DailyDoctor Archive Specialties Get app
All ophthalmology briefings

The edition · Ophthalmology

No intracameral antibiotic regimen stood out across nearly a million Swedish cataract operations

Endophthalmitis was 0.013% overall, with cefuroxime, cefuroxime plus ampicillin and moxifloxacin all within a narrow range. Also: carbide-gun eye burns treated with early amniotic membrane, OCT angiography as an early glaucoma progression signal, and an FDA generic tafluprost supplement.

The edition in brief

The Swedish National Cataract Register recorded 131 cases of endophthalmitis in 979,534 operations between 2018 and 2024, an incidence of 0.013%. Rates were 0.017% with intracameral cefuroxime alone, 0.011% with cefuroxime plus ampicillin and 0.010% with moxifloxacin; no regimen was significantly better. Enterococcal infection was more frequent with cefuroxime, and moxifloxacin cases more often regained 20/40 vision. The choice of agent matters less than giving one. An Indian tertiary centre treated 20 eyes burned by carbide guns during Diwali with irrigation, medical therapy and early overlay amniotic membrane; all epithelialised, vision improved from logMAR 1.77 to 0.77 at three months, and the one eye that presented late was lost. In 180 glaucoma eyes followed for five years, OCT angiography vessel density flagged progression a mean 2.3 years before visual fields, with somewhat lower specificity than OCT. The FDA recorded a supplement to Sandoz's generic tafluprost application, an administrative action. The pearl: irrigate a chemical eye injury before anything else.

In this edition

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this one is waiting in it.

QR code to install Daily Doctor
Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.

Tomorrow morning, before your first patient

One edition a day for ophthalmology, written by the desk, every claim tied to its paper. Six minutes.

Get the app — free